Stock Graphs and Charts
This is a complete list of financial data submitted by Antares Pharma, Inc. to the Securities and Exchange Commission (SEC) in their recent 10K and 10Q filings. These terms are taken from the XBRL portion of the filings.
Click on a term to see historical data and generate a time series chart from the historical filings.
Peers - Surgical and Medical Instruments and Apparatus (3841)
AMDA / Amedica Corporation
CASM / CAS Medical Systems, Inc.
CYTX / Cytori Therapeutics, Inc.
DRIO / DarioHealth Corp
DSCI / Derma Sciences, Inc.
GID / GI DYNAMICS, INC.
HART / Harvard Apparatus Regenerative Technology, Inc.
ICAD / icad, inc.
MDXG / MiMedx Group, Inc.
Related News Stories
Performance of the Core Biotech Model Account is currently tracking just ahead of the IBB and XBI over the same period of time. (749-7)
The rollercoaster ride in the gene therapy space (pessimism due to clinical hold/safety fears followed by optimism over Novartis acquiring AveXis) has been an interesting case study to watch. (698-0)
In this new series, I address stocks that ROTY members have asked about in live chat. (237-0)
Conatus (NASDAQ:CNAT) shares tumbled after the company announced top-line results from a phase 2b POLT-HCV-SVR clinical study. The phase 2b study was evaluating CNAT’s lead product candidate emricasan, a first-in-class pan-caspase protease inhibitor designed to reduce the activity of human caspases in liver transplant patients with fibrosis or cirrhosis. It is one of the four studies CNAT is currently conducting with its lead product candidates. (351-1)
Esperion Therapeutics (NASDAQ:ESPR) shares have moved up sharply after the company announced top-line results from a phase 2 study (1002-039) evaluating the LDL-C lowering efficacy and safety of bempedoic acid 180 mg added-on to stable background therapy of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in 58 patients with hypercholesterolemia. (158-3)